Regulatory & Legal

A landmark UK study reveals an AI diagnostic tool that predicts heart attacks with stunning accuracy and offers a £25 million lifeline to strained health budgets.

OMRON's new global ECG strategy leverages AI and key acquisitions to tackle heart disease, aiming to eliminate adverse cardiovascular events.

BW LPG declared a solid dividend, yet its stock fell. We dissect the numbers, peer strategies, and market forces to see what this reveals about the shipping giant.

With two key drug approvals, Sanofi isn't just treating rare diseases in China; it's executing a playbook that redefines market entry and dominance.

A rival bid reshaped a major gold merger, creating a West African powerhouse. Here’s how the deal was saved and what it means for the market.

The return of a pharma-finance veteran to MediPharm's board isn't just a personnel change; it's a strategic move to secure its global pharmaceutical ambitions.

South Korean tobacco giant KT&G just earned a flawless 'AAA' ESG rating, a first for its industry. What does this mean for investors and sustainability?

Tariff relief was a temporary fix. A powerful federal tax credit offers farmers a sustained way to fund the innovation they perform every day.

Ancient remedies meet modern AI. See how companies are using data and smart factories to transform traditional Chinese medicine into a global pharma force.

FC Supra du Québec isn't just building a team; it's building a brand. Their first signings reveal a bold, local-first strategy to win Quebec's heart.

With FDA approval and $80M in funding, ProVerum’s ProVee system aims to disrupt the BPH treatment market by prioritizing safety and patient quality of life.

After major setbacks, a surge of innovative drugs is set to transform the ALS market. We decode the science, the money, and what it means for patients.

With a 2026 launch looming, Nuvalent adds a proven oncology dealmaker to its board, signaling a strategic pivot from R&D to market assault.

A small biotech is challenging oncology's giants with a drug that targets cancer's core weakness, offering new hope to the sickest lung cancer patients.

Micro-cap BSEG racks up awards against giants like Variety, but with a volatile stock and weak fundamentals, can creative success spark a financial turnaround?

A new report shows slow progress on fixing ERs and long-term care, raising questions about government accountability and the real-world cost to Ontarians.

The eyewear giant is moving beyond frames, partnering to design custom chips. A strategic pivot to open-source hardware aims to redefine the market.

A landmark defense contract for 100,000 night-vision devices in Europe signals a major leap in military tech and raises the bar for NATO interoperability.

A new campaign tackles undiagnosed kidney disease. But is it just public health, or a savvy strategy to reshape a multi-billion dollar market?

A regulatory filing reveals a key investor's move as Alkermes' $2.1B bid for Avadel and its blockbuster narcolepsy drug, LUMRYZ, nears its final act.